Prolonged Release Evaluation of an Injectable Anticancer Drug using Human Serum Albumin Nanoparticle

Document Type: Article

Authors

1 Nanotechnology and advanced materials department, Materials and energy research center, Karaj, Iran

2 Department of Nanotechnology and Advanced Materials, Materials and Energy Research Center, Karaj, Iran

3 Ceramic department, Materials and energy research center, Karaj, Iran

4 Nanotechnology and Advanced Materials Department, Materials and Energy Research Center, Karaj, Iran

Abstract

Human serum albumin nanoparticles (HSA-NPs) were synthesized using the modified desolvation method. Fourier transform infrared spectroscopy (FT-IR), electronic absorption spectroscopy (UV-Vis), Zeta Sizer as well as field emission scanning electron microscope (FE-SEM) of the sample confirmed the formation of HSA NPs with an average size of 68 nm. The obtained results shown that HSA-NPs was successfully synthesized. The cytotoxic study of HSA-NPs in the HFFF2, normal cell lines was conducted and cell viability percentage demonstrated more than 90% within 24 h. Therefore, the synthesized NPs were nontoxic compared to the control samples. Furthermore, the release of the oxaliplatin as an anticancer drug incorporated in HSA NPs was also investigated in physiological conditions. The drug loading (DL) and drug entrapment efficiency (DEE) were enhanced and the DL of 0.9% and DEE of 51% are achievable. The Higuchi model was shown the best fitting compared to the different kinetically release model. This result and result of cyclic voltammetry indicated that the drug release mechanism followed by diffusion manner. Therefore, our present study showed that the biocompatible HSA NPs could improve prolonged release of oxaliplatin as anticancer drugs.

Graphical Abstract

Prolonged Release Evaluation of an Injectable Anticancer Drug using Human Serum Albumin Nanoparticle

Keywords

Main Subjects